GlassScriptPhysician profile
Rajesh V Dalal
NPI 1316928021
$6,919.94
in general payments reported to CMS, 2019-2025
54 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $233 · 2021: $1,696 · 2022: $1,013 · 2023: $928 · 2024: $968 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Education: $34.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.29 |
| Education | $34.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,072.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $518.72 | 2019-2021 | |
| Amgen INC. | $439.77 | 2021-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $403.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Nestle Healthcare Nutrition INC. | $275.66 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $265.43 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $240.97 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $229.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $198.50 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $185.29 | 2019-2021 | |
| Mylan Specialty L.P. | $160.78 | 2019-2024 | Yupelri |
| Boston Scientific Corporation | $148.20 | 2019-2022 | |
| Cipla USA INC. | $121.49 | 2021 | |
| Abbvie INC. | $113.25 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $85.10 | 2019-2024 | Arexvy, Trelegy Ellipta |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.